As a follow-up to our previous cross-sectional study, we used the longitudinal data from the National Alzheimer’s Disease Coordinating Center (NACC) [13, 14] to determine whether ACE inhibitors are associated with a differential risk for the development of AD in ApoE4 carriers versus non-carriers. This evidence concerns the gene APOE and Alzheimer disease.